Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib
Xiaofei Wang(Louisiana State University Health Sciences Center New Orleans), Ji Ming Wang(Frederick National Laboratory for Cancer Research), Keqiang Chen(Wuhan University of Technology), Qing Yun Li(Unknown), Yi Xiang(Ruijin Hospital), Jiaqiang Huang(Beijing Jiaotong University), Ying Yu(Nantong University), Min Zhou(Shanghai Jiao Tong University), Jae‐Hong Kim(Yonsei University), Wanghua Gong(Leidos (United States)), Thomas J. Sayers(Science Applications International Corporation (United States)), Poonam Tewary(Leidos (United States)), Beili Gao(Ruijin Hospital), Guochao Shi(Shanghai Jiao Tong University)
Cited by 16
Related Papers
International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the Formyl Peptide Receptor (FPR) Family
|Pharmacological Reviews|2009|770
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Caspase‐3 regulates the migration, invasion and metastasis of colon cancer cells
|International Journal of Cancer|2018|317
Smoking and microbiome in oral, airway, gut and some systemic diseases
|Journal of Translational Medicine|2019|314
Biofilm formation and its implications on the properties and fate of microplastics in aquatic environments: A review
|Journal of Hazardous Materials Advances|2022|245